Coprine is a naturally occurring mycotoxin and non-proteinogenic amino acid derivative found primarily in the ink cap mushroom Coprinopsis atramentaria (formerly Coprinus atramentarius), characterized by its chemical formula C₈H₁₄N₂O₄ and structure as N⁵-(1-hydroxycyclopropyl)-L-glutamine.[1][2] Upon ingestion, coprine is metabolized in the body to 1-aminocyclopropanol, which irreversibly inhibits the enzyme aldehyde dehydrogenase, leading to a disulfiram-like reaction if alcohol is consumed shortly afterward.[1][3]This compound's most notable effect is the induction of acute alcohol intolerance, with symptoms typically manifesting 30 minutes to several hours after ethanol ingestion and persisting for up to 6–24 hours, including facial flushing, nausea, vomiting, headache, tachycardia, hypotension, dizziness, and in severe cases, dyspnea or palpitations.[3] The reaction arises from the accumulation of acetaldehyde, a toxic metabolite of ethanol, due to the enzyme inhibition, mirroring the pharmacological action of the drug disulfiram used in alcohol aversion therapy.[1] Without alcohol consumption, coprine itself is not acutely toxic, and C. atramentaria mushrooms are otherwise edible when young, though confusion with similar edible species like Coprinus comatus can lead to unintended exposure.[3] Animal studies, such as those in mice, have confirmed coprine's ability to produce hyperaldehydemia (elevated acetaldehyde levels) post-ethanol administration, supporting its mechanism without direct in vitroenzyme inhibition by the parent compound.[2]Coprine's presence is limited to certain basidiomycete fungi, with reports also in the nematode Caenorhabditis elegans, but it poses a primary risk in mycology and foraging contexts due to the mushroom's widespread distribution in North America and Europe.[1]Treatment for coprine-induced reactions is supportive, involving hydration, electrolyte replacement, and avoidance of alcohol, with symptoms generally resolving without long-term sequelae.[3] As a mycotoxin, coprine exemplifies the dual nature of edible fungi, highlighting the importance of species identification to prevent adverse interactions.[3]
Chemical Properties
Molecular Structure
Coprine is a non-proteinogenic L-α-amino acid with the molecular formula C₈H₁₄N₂O₄. Its systematic IUPAC name is (2S)-2-amino-5-[(1-hydroxycyclopropyl)amino]-5-oxopentanoic acid, reflecting its derivation from L-glutamine through substitution of one hydrogen on the side-chain amidenitrogen with a 1-hydroxycyclopropyl group. This substitution results in the structure where the glutamine backbone—featuring an α-amino carboxylic acid and a modified γ-amide—is linked via the amidenitrogen to the three-membered cyclopropane ring bearing a hydroxyl group at the 1-position.[4]The key structural feature of coprine is the 1-hydroxycyclopropyl moiety, which imparts a cyclopropanol-like functionality and distinguishes it as the first known natural cyclopropanone equivalent-containing secondary metabolite.[4] The cyclopropane ring is strained due to its small size, contributing to the molecule's unique reactivity, while the hydroxyl group is attached directly to one of the ring carbons, forming an N-(1-hydroxycyclopropyl) amide linkage that enhances stability compared to free cyclopropanols.[4]Coprine exhibits stereochemistry primarily at the α-carbon of the glutamine-derived portion, occurring as the L-enantiomer with (S) configuration. The cyclopropane ring itself lacks chirality due to its symmetric substitution.
Physical and Chemical Characteristics
Coprine appears as a white crystalline solid. Its molecular weight is 202.21 g/mol, and it melts at 197–199 °C.[5][1] The compound demonstrates moderate watersolubility, estimated at approximately 76 g/L, but dissolves readily in polar organic solvents such as ethanol and DMSO.[5][6]Chemically, coprine exhibits stability in neutral environments but undergoes hydrolysis in acidic or basic conditions, yielding cyclopropanone derivatives as key products.[7] This reactivity stems from its cyclopropanone equivalent. It displays UV absorbance at 220 nm.[6]Spectroscopic analyses further characterize coprine. Infrared (IR) spectroscopy reveals a characteristic carbonyl stretch at 1700 cm⁻¹.[6]Nuclear magnetic resonance (NMR) data include proton signals for cyclopropane protons at 0.8–1.2 ppm and hydroxyl protons at 4–5 ppm, alongside carbon-13 shifts for cyclopropane carbons at 10–20 ppm and carbonyls at 170–180 ppm.[6] These data are reported in chemical databases and original studies.Isolation and purification of coprine present challenges owing to its co-occurrence with various mushroom metabolites in natural sources, often necessitating advanced chromatographic techniques for high purity.[4]
Occurrence and Biosynthesis
Natural Sources
Coprine is primarily produced by mushrooms in the genus Coprinopsis, with the highest concentrations found in Coprinopsis atramentaria (common inkcap or tippler's bane), a saprotrophic fungus that grows in dense clusters.[1][8] It is also present at lower levels in other species, such as Coprinopsis insignis.[9]These fungi are widespread across temperate regions of Europe, North America, and Asia, often emerging after rain from spring to autumn in urban and natural habitats.[10][11] They typically colonize decaying hardwood, buried wood, lawns, and disturbed grasslands, contributing to nutrient recycling as decomposers.[12] Coprine concentrations vary by developmental stage, reaching up to approximately 150 mg per kg of fresh mushroom weight in young caps of C. atramentaria, where it is most abundant before deliquescence occurs.[13]Quantification of coprine in these mushrooms is achieved through analytical techniques such as high-performance liquid chromatography (HPLC) or liquid chromatography-mass spectrometry (LC-MS), which detect the compound in both raw and processed samples.[14][15] Cooking does not degrade coprine, preserving its presence and potential bioactivity post-preparation.[16]Ecologically, coprine likely functions as a mycotoxin defense, deterring herbivory by mammals and possibly inhibiting microbial competitors through its toxic metabolites.[17] This role aligns with the structural uniqueness of coprine as a cyclopropyl-containing amino acid derivative, enhancing its protective utility in fungal fruiting bodies.[8]Coprine has also been reported in non-fungal organisms, such as the nematode Caenorhabditis elegans.[1]
Biosynthetic Pathway
Coprine is produced in certain species of the fungal genus Coprinopsis, notably C. atramentaria, through a biosynthetic process rooted in glutaminemetabolism as a secondary metabolite. The compound's structure consists of L-glutamine with a 1-hydroxycyclopropyl group attached via an amide bond to the side-chain nitrogen, indicating that biosynthesis likely involves modification of glutamine's gamma-carboxamide group.[4][1]The key steps in coprine formation are not fully elucidated, but available evidence points to the incorporation of a cyclopropane-containing unit, possibly 1-aminocyclopropanol, onto a glutamine precursor, potentially via amidotransfer mechanisms analogous to those in other fungal amino acid derivatives. This process is regulated as part of fungal secondary metabolism, though specific enzymes, such as potential cyclopropane synthase-like proteins, have not been identified.[18]Genetically, the pathway is believed to involve clustered genes in the Coprinopsis genome responsible for cyclopropane ring assembly and linkage, with initial structural insights from isolation studies in the 1970s. However, modern genomic confirmation is lacking, as the genome of coprine-producing species like C. atramentaria remains unsequenced, unlike the related model species C. cinerea.[4][19]Production variations occur across species, with lower coprine yields in some Coprinopsis taxa potentially resulting from incomplete or repressed pathway expression under differing environmental conditions.[18]
Toxicological Effects
Clinical Symptoms
Ingestion of coprine alone produces no symptoms in humans or animals, even at relatively high doses, as the toxin requires interaction with alcohol to elicit effects.[8]When alcohol is consumed following coprine ingestion—typically within 24 to 72 hours—a disulfiram-like reaction occurs, with symptoms onset ranging from 5 to 120 minutes after alcohol intake.[8][20] Common manifestations include facial flushing, tachycardia, hypotension (in rare cases), nausea, vomiting, headache, metallic taste in the mouth, malaise, chest pain, shortness of breath, and occasionally syncope or dysrhythmias.[8][20] These symptoms generally peak within the first few hours and resolve within 30 minutes to 24 hours, though milder effects may persist up to 3 days; the underlying enzyme inhibition can last 2 to 5 days, potentially reactivating symptoms with subsequent alcohol exposure.[8]The severity of the reaction is dose-dependent, influenced by the quantity of coprine-containing mushrooms consumed and the amount of alcohol ingested, with even small amounts of ethanol (as low as 5 mg/dL blood level) sufficient to trigger effects in sensitized individuals.[21] No fatalities from coprine poisoning have been reported, and cases are generally self-limited with supportive care, though annual reports to poison centers in regions like the United States number fewer than a dozen.[8][22] In Germany, coprine-related incidents from species such as Coprinopsis atramentaria (often cooked) contribute to non-fatal mushroom poisonings, with national data from 2000 to 2018 documenting thousands of hospitalizations overall but none lethal for this syndrome.[22] Case series, such as one involving five patients who experienced flushing, headache, tachycardia, and dyspnea after consuming related mushrooms like Lepiota aspera followed by alcohol, highlight the reaction's rapid onset and resolution within hours, with recurrence possible up to 48 hours later.[23]
Mechanism of Action
Coprine functions as a prodrug that undergoes hydrolysis in vivo to yield 1-aminocyclopropanol, which subsequently tautomerizes to cyclopropanone hydrate. This active metabolite acts as an electrophile, leading to irreversible covalent inhibition of aldehyde dehydrogenase (ALDH) through modification of the enzyme's active site.[24][25]The covalent binding occurs via electrophilic attack on the thiol group of a key cysteine residue (Cys302 in human ALDH2), forming a stable adduct that blocks the enzyme's catalytic activity. This inhibition specifically prevents the oxidation of acetaldehyde to acetate, a critical step in alcohol metabolism, as represented by the following reaction:\ce{CH3CHO + NAD+ + H2O ->[ALDH] CH3COOH + NADH + H+}The process is halted due to the inactivated enzyme, resulting in acetaldehyde accumulation when alcohol is consumed.[24][25]Coprine exhibits selectivity for ALDH isoforms, primarily targeting the low-Km mitochondrial form (ALDH2) responsible for acetaldehyde detoxification, with inhibition also observed in cytosolic isoforms under certain conditions, such as with alternative substrates like 3,4-dihydroxyphenylacetaldehyde. High-Km activities with acetaldehyde remain largely unaffected in liver and brain. Unlike disulfiram, coprine shows minimal impact on other enzymes, including no inhibition of alcohol dehydrogenase (ADH) or dopamine β-hydroxylase.[24][26]Due to the irreversible nature of the inhibition, ALDH activity recovers gradually over several days through de novo synthesis of the enzyme.[24]
History and Research
Discovery and Isolation
The disulfiram-like effects of Coprinus atramentaria (now classified as Coprinopsis atramentaria) when consumed with alcohol were first speculated upon in scientific literature in 1956, based on unreplicated folk reports suggesting the presence of a compound similar to disulfiram in the mushroom.[27] These early observations highlighted an alcohol intolerance syndrome but lacked chemical identification of the responsible agent. In 1974, Swedish researchers confirmed the interaction through clinical and experimental studies on human subjects and animals, establishing it as a reliable physiological response rather than anecdotal variation.[4]The active compound, coprine, was successfully isolated in 1975 by a team of Swedish researchers including P. Lindberg, R. Bergman, and B. Wickberg at Lund University. They extracted it from dried fruiting bodies of C. atramentaria using a combination of solvent extraction, chromatography, and crystallization techniques, achieving a yield of 0.1-0.3% by dry weight. The structure was elucidated shortly thereafter via X-ray crystallography of a derivatized form, revealing coprine as N^5-(1-hydroxycyclopropyl)-L-glutamine, a novel cyclopropanone derivative. This isolation marked the first definitive identification of the toxin responsible for the syndrome.[4][2]Coprine was formally named in 1975 following its structural characterization. Early purification efforts were hampered by the compound's inherent instability, particularly the reactive cyclopropanone ring, which degraded under standard isolation conditions and led to numerous failed attempts in the years prior to 1975. In 1979, further studies verified the mechanism of action through experiments involving radiolabeled analogs, demonstrating coprine's in vivohydrolysis to 1-aminocyclopropanol, an irreversible inhibitor of aldehyde dehydrogenase.[25]
Therapeutic Investigations
In the 1970s and 1980s, coprine was investigated as a potential alternative to disulfiram for treating alcoholism, leveraging its natural occurrence in mushrooms and its ability to induce an aversive reaction to alcohol through aldehyde dehydrogenase (ALDH) inhibition.[28] Animal studies in rats demonstrated that coprine administration prior to ethanol exposure produced a potent disulfiram-like effect, significantly elevating acetaldehyde levels and causing cardiovascular responses such as hypotension and tachycardia, which effectively reduced voluntary alcohol intake in short-term aversion models.[29] These findings suggested coprine's efficacy as a short-term deterrent, with its effects being reversible upon cessation, unlike disulfiram's more persistent inhibition.[28]However, therapeutic development was abandoned due to safety concerns identified in animal models. Studies in rats and dogs revealed coprine's long-term genotoxicity, including chromosomal aberrations and DNA damage from chronic exposure, alongside gonadotoxic effects such as severe testicular injury.[30] These mutagenic properties, observed in 1980s toxicological evaluations, outweighed its potential benefits, leading to the conclusion that coprine was unsuitable for clinical use.[31]Recent research from 2020 to 2025 has primarily referenced coprine in the context of mushroom poisoning reviews rather than active therapeutic exploration, with no ongoing clinical trials identified.[32] For instance, a 2025 update in Turkish emergency medicine literature categorizes coprine as a key toxin in alcohol-related mushroom syndromes but does not propose medical applications.[33] Broader interest persists in ALDH inhibitors as adjuncts to cancer therapy, where they target cancer stem cells and enhance chemotherapysensitivity, though coprine itself has not advanced beyond preclinical consideration due to its toxicity profile.[34]Coprine remains unapproved for any therapeutic purpose and is instead monitored in mycology and toxicology for poisoning prevention, emphasizing its risks over benefits.[28]